YITU Attended ICCV 2019 with Self-developed Cloud AI Chip, Showcasing Integrated Software and Hardware Strength
1.11.2019 13:00:00 EET | Business Wire | Press release
The 17th International Conference on Computer Vision (ICCV 2019) was convened in Seoul, South Korea this week. YITU Technology attended the conference with its latest researches. Known as the world’s top-notch computer vision conference, ICCV is held once every two years, of which the papers and topics manifest the highest research level and technical growth trend in the field of computer vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191101005240/en/
YITU AI chip QuestCore TM (Photo: Business Wire)
As a globally leading artificial intelligence company, YITU has been always standing at the frontier of AI innovations. From October 29th to November 1st, AI researchers from YITU present their up-to-date research findings and industrial practices at the ICCV 2019, including QuestCoreTM, a cloud AI chip developed by YITU, so as to communicate with and learn from a wider range of research communities.
“The peak of artificial intelligence algorithm performance has shifted from academia to industry,” said Dr. Yan Shuicheng, CTO of YITU, “Academia and industry need in-depth cooperation, to better boost increasing peak performance of the entire AI ecological algorithm.”
As a world-known scholar in computer vision and machine learning, Dr. Yan joined YITU in August this year, the company's strong R&D and engineering strength is one of the important reasons for him to join. Dr. Yan, as an IEEE Fellow, IAPR Fellow and ACM Distinguished Scientist, has published more than 600 papers in top international journals and conferences, with more than 40,000 citations, H-index 98.
YITU released its self-developed cloud AI chip QuestCoreTM in May, 2019. Integrated with its world-class AI algorithm and advanced chip design philosophy, it is so far the most intelligent and cost-effective video analysis chip in the world. This chip indicates a successful practice of YITU to follow the strong coupling trend between AI algorithms and chip design. Relevant achievements are also exhibited on ICCV 2019.
According to data from Tsinghua University, computer vision applications accounted for nearly 35% of the total artificial intelligence applications in 2019, and have become an important support for the development of various industries.
YITU is building the Visual Computing National New Generation Artificial Intelligence Open Innovation Platforman, a national AI infrastructure, to align with the developers of algorithm, chip and product, and provide full chain optimization services covering algorithm, chip and entire tool chain.
“We will help to enhance the overall performance of visual computing smart industry solution,” said Dr. Yan Shuicheng. “Help to integrate development experience and domain knowledge, and promote industrial innovation and cooperation."
About YITU
YITU Technology is one of the few startups in the world that has pioneered many cutting-edge technologies in many critical Artificial Intelligent (AI) fields such as computer vision, speech recognition, natural language processing, intelligent decision-making and AI chips.
YITU Technology is dedicated to advancing breakthrough technologies in AI. Powered by world-class AI algorithms, YITU's self-developed AI chip QuestCore™ can be applied to a variety of scenarios to provide cost-effective and market-competitive solutions. YITU is the only company worldwide to be awarded championship in facial recognition vendor test three times by National Institute of Standards and Technology (NIST), as well as first place in the test hosted by the Intelligence Advanced Research Projects Activity (IARPA). YITU’s self-developed speech recognition technology has been tested to be best-in-class for the Mandarin language. Nature Medicine, a leading academic journal, published on YITU’s latest breakthrough in intelligent pediatric diagnostic technology based on NLP this February, which has been so far the highest-level paper in the field of artificial intelligence research in China.
Leveraging AI technology, YITU is empowering diverse industries. It provides world-leading innovative technologies and products in several sectors including Intelligent City, Smart Finance, Intelligent Healthcare, Smart Retail, AI Chips and AI Pharmaceuticals. YITU is so far the only AI company nationwide able to provide intelligent management technology in mega-cities and complex conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005240/en/
Contact information
Yitu Tech
Contact name: Alice Deng
Tel:021 - 52559588
Email:media@yitu-inc.com
Website: https://www.yitutech.com/en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom